Neuberger Berman Group LLC Has $4.58 Million Holdings in Alkermes plc $ALKS

Neuberger Berman Group LLC trimmed its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 22.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 152,721 shares of the company’s stock after selling 43,610 shares during the period. Neuberger Berman Group LLC’s holdings in Alkermes were worth $4,582,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. American Century Companies Inc. boosted its holdings in Alkermes by 20.2% in the third quarter. American Century Companies Inc. now owns 4,397,471 shares of the company’s stock worth $131,924,000 after acquiring an additional 740,248 shares in the last quarter. Capital Fund Management S.A. bought a new stake in shares of Alkermes during the second quarter valued at approximately $1,142,000. Public Sector Pension Investment Board increased its holdings in shares of Alkermes by 11.6% during the third quarter. Public Sector Pension Investment Board now owns 710,700 shares of the company’s stock valued at $21,321,000 after acquiring an additional 73,787 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Alkermes by 38.9% during the third quarter. New York State Common Retirement Fund now owns 195,999 shares of the company’s stock worth $5,880,000 after purchasing an additional 54,915 shares during the period. Finally, Allianz Asset Management GmbH raised its position in shares of Alkermes by 3,908.2% during the third quarter. Allianz Asset Management GmbH now owns 524,795 shares of the company’s stock worth $15,744,000 after purchasing an additional 511,702 shares during the period. Institutional investors own 95.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Royal Bank Of Canada reduced their price target on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Wall Street Zen cut shares of Alkermes from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. HC Wainwright reissued a “neutral” rating and set a $43.00 price objective on shares of Alkermes in a report on Thursday, February 26th. Finally, Truist Financial increased their price objective on Alkermes from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Alkermes presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.07.

Insiders Place Their Bets

In related news, SVP Christian Todd Nichols sold 6,000 shares of Alkermes stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $30.00, for a total transaction of $180,000.00. Following the sale, the senior vice president directly owned 109,769 shares in the company, valued at approximately $3,293,070. This trade represents a 5.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Shane Cooke sold 61,200 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total value of $2,115,684.00. Following the completion of the transaction, the director directly owned 103,744 shares in the company, valued at approximately $3,586,430.08. This represents a 37.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 157,434 shares of company stock worth $5,305,794 over the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Alkermes Price Performance

NASDAQ ALKS opened at $28.63 on Friday. The company has a fifty day moving average price of $31.60 and a 200-day moving average price of $30.24. The firm has a market cap of $4.77 billion, a price-to-earnings ratio of 20.02, a PEG ratio of 7.14 and a beta of 0.53. Alkermes plc has a 1 year low of $25.17 and a 1 year high of $36.32.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The firm had revenue of $384.55 million for the quarter, compared to the consensus estimate of $380.44 million. During the same period in the previous year, the business earned $1.05 earnings per share. The firm’s revenue for the quarter was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, research analysts anticipate that Alkermes plc will post 1.31 EPS for the current fiscal year.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.